JP2003534282A - 神経変性及び他の神経学的疾患の治療における使用のためのアポトーシス体 - Google Patents

神経変性及び他の神経学的疾患の治療における使用のためのアポトーシス体

Info

Publication number
JP2003534282A
JP2003534282A JP2001585781A JP2001585781A JP2003534282A JP 2003534282 A JP2003534282 A JP 2003534282A JP 2001585781 A JP2001585781 A JP 2001585781A JP 2001585781 A JP2001585781 A JP 2001585781A JP 2003534282 A JP2003534282 A JP 2003534282A
Authority
JP
Japan
Prior art keywords
cells
apoptotic
disease
patient
bodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2001585781A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003534282A5 (enExample
Inventor
ダニエル・ソーダー
アルカディー・マンデル
アンソニー・イー・ボルトン
Original Assignee
ヴァソゲン アイルランド リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヴァソゲン アイルランド リミテッド filed Critical ヴァソゲン アイルランド リミテッド
Publication of JP2003534282A publication Critical patent/JP2003534282A/ja
Publication of JP2003534282A5 publication Critical patent/JP2003534282A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/414—Nervous system antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2001585781A 2000-05-25 2001-05-25 神経変性及び他の神経学的疾患の治療における使用のためのアポトーシス体 Withdrawn JP2003534282A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA2,309,424 2000-05-25
CA 2309424 CA2309424A1 (en) 2000-05-25 2000-05-25 Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders
PCT/CA2001/000759 WO2001089537A2 (en) 2000-05-25 2001-05-25 Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders

Publications (2)

Publication Number Publication Date
JP2003534282A true JP2003534282A (ja) 2003-11-18
JP2003534282A5 JP2003534282A5 (enExample) 2008-07-10

Family

ID=4166243

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001585781A Withdrawn JP2003534282A (ja) 2000-05-25 2001-05-25 神経変性及び他の神経学的疾患の治療における使用のためのアポトーシス体

Country Status (12)

Country Link
US (3) US7132285B2 (enExample)
EP (1) EP1289535B1 (enExample)
JP (1) JP2003534282A (enExample)
AT (1) ATE366581T1 (enExample)
AU (1) AU2001261987A1 (enExample)
CA (1) CA2309424A1 (enExample)
DE (1) DE60129322T2 (enExample)
DK (1) DK1289535T3 (enExample)
ES (1) ES2290134T3 (enExample)
PT (1) PT1289535E (enExample)
TW (1) TWI239843B (enExample)
WO (1) WO2001089537A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2309518A1 (en) * 2000-05-25 2001-11-25 Vasogen Ireland Limited Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders
TWI281407B (en) * 2000-09-18 2007-05-21 Vasogen Ireland Ltd Apoptosis-mimicking synthetic entities and use thereof in medical treatment
CA2333494A1 (en) * 2001-02-01 2002-08-01 Vasogen Ireland Limited Blood brain barrier modulation
EP1429727A1 (en) * 2001-09-18 2004-06-23 Vasogen Ireland Limited Apoptosis-mimicking synthetic entities and use thereof in medical treatment
US20060008517A1 (en) * 2004-07-09 2006-01-12 Lynch Marina A Treatment of age-related memory impairment
US11512289B2 (en) 2015-02-18 2022-11-29 Enlivex Therapeutics Rdo Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11000548B2 (en) * 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
JP6803339B2 (ja) 2015-04-21 2020-12-23 エンリヴェックス セラピューティクス リミテッド 治療用のプールされた血液アポトーシス細胞調製物及びそれらの使用
JP6884155B2 (ja) 2016-02-18 2021-06-09 エンリヴェックス セラピューティクス リミテッド 癌治療のための併用免疫療法及びサイトカイン制御療法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ249176A (en) * 1992-02-07 1996-11-26 Vasogen Inc Method of increasing concentration of nitric oxide in blood using ozone and uv radiation
US5980954A (en) 1992-02-07 1999-11-09 Vasogen Ireland Limited Treatment of autoimmune diseases
US6696092B2 (en) * 1992-02-07 2004-02-24 Vasogen Ireland Limited Endothelial lining effects and treatment of vasospastic disorders
NZ512849A (en) * 1999-01-12 2003-02-28 Ct De Rech Du Ct Hospitalier D Pre-conditioning against cell death
CA2271190A1 (en) * 1999-05-06 2000-11-06 Vasogen Ireland Limited Improved method for treating mammals with modified mammalian blood
NZ520889A (en) 2000-03-07 2004-05-28 Mechanical connection of panels
CA2309417A1 (en) * 2000-05-25 2001-11-25 Anthony E. Bolton Apoptotic entities for use in treatment of endothelium dysfunction disorders
CA2309518A1 (en) * 2000-05-25 2001-11-25 Vasogen Ireland Limited Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders
US7122208B2 (en) * 2001-04-06 2006-10-17 Vasogen Ireland Limited Compositions containing apoptotic entities
JP2005517637A (ja) * 2001-11-29 2005-06-16 セラコス・インコーポレイテッド 体外フォトフォレーシスおよび／またはアポプトーシス細胞による一定の被験体を前処理するための方法
US7255880B2 (en) * 2003-04-03 2007-08-14 Vasogen Ireland Limited Treatment of endothelin-related disorders

Also Published As

Publication number Publication date
DK1289535T3 (da) 2007-11-05
ES2290134T3 (es) 2008-02-16
EP1289535B1 (en) 2007-07-11
ATE366581T1 (de) 2007-08-15
TWI239843B (en) 2005-09-21
US20020044924A1 (en) 2002-04-18
US20070087010A1 (en) 2007-04-19
DE60129322T2 (de) 2008-03-13
PT1289535E (pt) 2007-10-19
DE60129322D1 (de) 2007-08-23
US20080131416A1 (en) 2008-06-05
WO2001089537A3 (en) 2002-08-01
EP1289535A2 (en) 2003-03-12
AU2001261987A1 (en) 2001-12-03
US7132285B2 (en) 2006-11-07
HK1055080A1 (en) 2003-12-24
CA2309424A1 (en) 2001-11-25
WO2001089537A2 (en) 2001-11-29

Similar Documents

Publication Publication Date Title
US20080131416A1 (en) Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders
Paterniti et al. Docosahexaenoic acid attenuates the early inflammatory response following spinal cord injury in mice: in-vivo and in-vitro studies
JP2003534281A (ja) Ｔ細胞媒介性及び炎症性疾患の治療における使用のためのアポトーシス体
EP0859628B1 (de) Medikament, insbesondere zur modulation der immunantwort bei der bekämpfung von viren, tumoren, bakterien und parasiten
Desai et al. Long term therapeutic effects of icariin‐loaded PLGA microspheres in an experimental model of optic nerve ischemia via modulation of CEBP‐β/G‐CSF/noncanonical NF‐κ B axis
US20080063631A1 (en) Apoptotic entities for use in treatment of endothelium dysfunction disorders
Abdeltawab et al. Effect of Moringa oleifera and ivermectin nanoparticles on the immunopathological response during experimental trichinosis in mice
CA2409960A1 (en) Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders
CA2409992A1 (en) Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders
HK1055080B (en) Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders
DE10038722C2 (de) Verfahren zur Reduzierung von spezifischen Immunreaktionen
HK1055079B (en) Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders
HK1093428A (en) Apoptotic entities for use in treatment of t-cell-mediated und inflammatory disorders
US20070298020A1 (en) Apoptotic entities for use in treatment of endothelium dysfunction disorders
CA2409994A1 (en) Apoptotic entities for use in treatment of endothelium dysfunction disorders
EP1179587A1 (de) Verfahren zur Reduzierung von spezifischen Immunreaktionen
US7524518B2 (en) Composition for promoting regeneration of hard tissues comprising an extract of cortex eucommiae
EP1299113A2 (de) Verwendungen des hitzeschockproteins gp96
DE102004047262A1 (de) Pharmazeutisches Mittel umfassend Blutprodukte und deren Verwendung als Injektions- oder Infusionsmittel zur Prophylaxe und Behandlung von Defekten des Immunsystems beim Menschen
EP1085085A1 (de) Verfahren zur Reduzierung von spezifischen Immunreaktionen

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20051117

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20051117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20051117

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20051212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080520

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080520

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20080818